The Cooper Companies (COO)
(Delayed Data from NSDQ)
$93.33 USD
+0.64 (0.69%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $93.32 -0.01 (-0.01%) 7:16 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.33 USD
+0.64 (0.69%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $93.32 -0.01 (-0.01%) 7:16 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
What's in Store for Cooper Companies (COO) Q1 Earnings?
by Zacks Equity Research
Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.
PCTEL (PCTI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
PCTEL's (PCTI) fourth-quarter performance is likely to have benefited from robust 5G scanning receiver business.
Ciena (CIEN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ciena's (CIEN) fiscal first-quarter performance is likely to have benefited from its global scale and diversification across geographies and customer segments.
Is a Beat in Store for ABM Industries' (ABM) Q1 Earnings?
by Zacks Equity Research
ABM Industries' (ABM) first-quarter fiscal 2020 revenues are likely to have benefited from organic growth.
Analysts Estimate Cooper Cos. (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cooper Cos. (COO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
Cooper Cos. (COO) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Cos. (COO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of 0.92% and 0.91%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Domo (DOMO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Domo's (DOMO) third-quarter fiscal 2020 results are expected to benefit from an expanding clientele and portfolio strength.
Okta (OKTA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Okta's (OKTA) continued investments are expected to have kept third-quarter fiscal 2020 margin under pressure despite higher adoption of Identity solutions.
Factors to Consider Ahead of Guidewire's (GWRE) Q1 Earnings
by Zacks Equity Research
Guidewire's (GWRE) Q1 results are expected to reflect gains from robust adoption of cloud-based InsurancePlatform suite of solutions. Rising expenditure on product enhancements might have been a drag.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) has likely gained from strength in Animal Health segment in the fiscal second quarter.
Coupa Software (COUP) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Coupa Software's (COUP) Q3 performance is likely to have gained from an expanding customer base, backed by sturdy adoption of Accelerate and virtual cards for POs.
Cooper Cos. (COO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cooper Cos. (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cooper Cos. (COO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health
by Zacks Equity Research
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Why Is Cooper Cos. (COO) Down 10.5% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MCK vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Apple, Chevron, VMware, Capital One and Cooper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Chevron, VMware, Capital One and Cooper
Top Research Reports for Apple, Chevron & VMware
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Apple (AAPL), Chevron (CVX) and VMware (VMW).